newsfilter
← Latest News
GlobeNewswire·

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive